Blood Screening Market Size to Soar to USD 5.07 Billion by 2030

Blood Screening Market, which is now well on its way towards unprecedented segmentation growth owing to the extensive rollout of new technologies and increasing demand amongst consumers due to the rise of infectious diseases worldwide. With a market size of roughly USD 2.92 billion in 2023, the market is expected to grow at a compound annual growth rate (CAGR) of 8.2% from 2024 to 2030.

Request Sample Link For More Details: https://www.maximizemarketresearch.com/request-sample/13686/

Market Estimation, Drivers, and Opportunities for Growth

Blood screening market is being driven positively by number of factors.

Blood donations help grow: Raising money schemes and awareness campaigns have all been implemented which means automated screening methods are a must to assure blood transfusions are safe and effective [26].

The continued emergence of infectious diseases like HIV and hepatitis as well as newly emerging pathogens make continued blood screening protocols absolutely critical.

Advancements in technology: Newer techniques, the use of nucleic acid amplification tests (NAT), and enzyme-linked immunosorbent assays (ELISA) have improved sensitivity and specificity of blood test and on development stage better blood tests with the shorter window period for infections.

Supportive policies and funding from governments across the world towards the establishment of blood screening infrastructure is fuelling market growth in developing regions.

Tracked 8 | U.S. Market and Investment Trends

Another seminal paper published in 2021 used native antigen substrates to show that a currently advanced blood screening assay can enhance accuracy in detecting blood-borne pathogens. FDA Approvals Characteristics of Some Advanced Blood Screening Assays with and without Automation Description All US and European FDA approvals up to date Function Pathogen Detection Assay Sensitivity Blood Safety Automation Platform Hospital level Import Permit required to import bloodContents4+More items.

Public-Private Partnerships: PPPs were created between government agencies and private companies to upscale the blood screening infrastructure and ensure immediate response and preparedness to any and all health emergencies.

Integration of Technology: Artificial intelligence (AI) and machine learning integration in blood screening process has been studied for predicting and detecting possible outbreaks of other infections changing the blood parameters, and enhancing preventive measures.

Get to Know More About This Market Study: https://www.maximizemarketresearch.com/market-report/blood-screening-market/13686/

Market Segmentation: Dominant Shares

On The basis of Technology, Product and Service, End-Users the Blood Screening Market is segmented. The nucleic acid test (NAT) segment accounts for the largest share of the market due to its high sensitivity and specificity for the viral nucleic acids detection. In terms of products & services, the reagents & kits held the largest share of market owing to repetitive need of reagents in screening processes.

Competitive Analysis

Segment-wise, the blood screening market is highly competitive, with leading players constantly innovating and investing to maintain their share:

Abbott Laboratories: Abbott is a leader in diagnostics, and has a well-established portfolio of blood screening assays that are expected to grow rapidly. The Alinity s System is a next-generation blood screening solution launched by the company in 2023 to improve blood screening sensitivity for infectious diseases elevating blood transfusion diagnostics to a higher standard of safety.

F. Hoffmann-La Roche Ltd: Roche is well known in the diagnostic space and purchased Tasso, Inc. in March 2023, a company that develops innovative blood collection technology. The intent behind this acquisition is to add solutions for the blood transfusion diagnostics portfolio of Roche for accurate and faster diagnostic solutions.

Thermo Fisher Scientific Inc: Thermo Fisher Scientific announced that it acquired Tx All; a specialist in transfusion medicine solutions focused on innovation. This acquisition is intended to expand Thermo Fisher's product portfolio in the blood transfusion diagnostics space, reinforcing its position in the field.

Ortho Clinical Diagnostics: Ortho Clinical Diagnostics Orion System is the latest innovative blood screening platform, developed to enhance the safety of transfusions by improving the efficiency of laboratories with fast blood banking accuracy.

Bio-Rad Laboratories - Bio-Rad Laboratories said it has acquired Quantitative Diagnostics to further support its transfusion medicine solutions and expand its presence in the blood transfusion diagnostics market.

Request Sample Link For More Details: https://www.maximizemarketresearch.com/request-sample/13686/

Regional Analysis

The blood screening market has the following regional characteristics:

United States - U.S. Market is expected to account for 38% of the total market by 2037, owing to high demand for blood transfusions and improved healthcare infrastructure. Apart from private investments, efforts by government in bolstering blood safety programs also fueled market expansion.

United Kingdom: Stringent regulations to ensure blood safety, investments in modernization of blood screening laboratories are anticipated to drive the growth of the market in the UK.

Germany: The country has a well-established healthcare system, and an emphasis on preventive healthcare, which has resulted in increasing adoption of advanced blood screening technologies to facilitate market expansion in the country.

France : Factors such as the presence of supportive government policies towards voluntary blood donation, and public awareness & education campaigns need are anticipated to create a positive outlook towards receiving positive neuroimaging in the country which in turn is expected to create a higher demand for blood screening products.

Japan: The increasing aged population has driven blood transfusion needs, leading to advances in blood screening technologies to meet the need and maintain safety of the supply.

China: With its more than ever infectious diseases, China is modernizing its blood screening facilities which also is aided by its rapid urbansation along with increasing healthcare investments.

Conclusion

Improvements With Technological Advancements, Strategic Investment & Governing Policies Fueling The Blood Screening Market Growth In Anticipation Of Record-Breaking Revenue In 2029. The focus on rapid detection of infectious diseases along with the introduction of technologies constitute huge growth opportunities for the market. Those companies that leverage the latest screening solutions in this space, while also working with the healthcare systems that will deploy them, will be uniquely positioned to lead the way in this rapidly evolving market.

For additional insights, visit:

♦ Disposable Endoscopes Market https://www.maximizemarketresearch.com/market-report/disposable-endoscopes-market/166820/

♦ Neurovascular Devices Market https://www.maximizemarketresearch.com/market-report/global-neurovascular-devices-market/31229/

♦ Nucleic Acid Extractors Market Overview https://www.maximizemarketresearch.com/market-report/global-nucleic-acid-extractors-market/89213/

♦ Powered Surgical Instruments Market https://www.maximizemarketresearch.com/market-report/global-powered-surgical-instruments-market/20319/

♦ Cryogenic Equipment Market https://www.maximizemarketresearch.com/market-report/global-cryogenic-equipment-market/25719/

Contact Maximize Market Research:

MAXIMIZE MARKET RESEARCH PVT. LTD.

⮝ 3rd Floor, Navale IT park Phase 2,
Pune Banglore Highway, Narhe
Pune, Maharashtra 411041, India.
✆ +91 9607365656
sales@maximizemarketresearch.com
www.maximizemarketresearch.com

About Maximize Market Research:

Maximize Market Research is one of the fastest-growing market research and business consulting firms serving clients globally. Our revenue impact and focused growth-driven research initiatives make us a proud partner of majority of the Fortune 500 companies. We have a diversified portfolio and serve a variety of industries such as IT & telecom, chemical, food & beverage, aerospace & defense, healthcare and others.

This release was published on openPR.